Back | Next |
home / stock / nbix / nbix message board
Subject | By | Source | When |
---|---|---|---|
I predict $NBIX will be $117.43 (or more) | Kagami | investorshub | 11/10/2017 5:45:48 AM |
Hi guys! Any forecasts on price targets? I'm contemplating | jtf3 | investorshub | 11/03/2017 8:47:06 PM |
$NBIX buy 50.20 | stocktrademan | investorshub | 07/27/2017 3:14:25 PM |
$NBIX bullish 52.71 | stocktrademan | investorshub | 05/11/2017 4:40:41 PM |
Nice win here!! Great news, should continue higher | rightothesky | investorshub | 04/12/2017 1:45:51 PM |
$52.28 NHOD!! | TheFinalCD | investorshub | 04/12/2017 1:12:47 PM |
Ya, that big buy at $49 was a | rightothesky | investorshub | 04/12/2017 12:04:21 PM |
HIT $51.99 SO FAR | TheFinalCD | investorshub | 04/12/2017 11:25:10 AM |
Wow. Sure is! | rightothesky | investorshub | 04/11/2017 10:12:22 PM |
9300 TRADE @ $49 | TheFinalCD | investorshub | 04/11/2017 10:08:01 PM |
Anyone wanna throw some predictions out there? | rightothesky | investorshub | 04/11/2017 10:04:35 PM |
FDA Approval........ | TheFinalCD | investorshub | 04/11/2017 10:02:55 PM |
Neurocrine Announces FDA Approval of INGREZZA (valbenazine) Capsules | TheFinalCD | investorshub | 04/11/2017 9:44:14 PM |
nice upside | gregque | investorshub | 04/11/2017 9:40:08 PM |
Ah movement on news | Awl416 | investorshub | 04/11/2017 9:30:20 PM |
This 10yr DCF implies Neurocrine Biosciences $NBIX is | ValueInvestor15 | investorshub | 02/14/2017 1:33:11 PM |
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are trading | AnthonyJackson | investorshub | 01/18/2017 2:41:39 PM |
AnthonyJackson6: Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) are trading lower by over 5% a | AnthonyJackson6 | investorshangout | 01/18/2017 2:36:05 PM |
Hattlem: $NBIX immediate resistance @ the 10 DMA but still looks like it wants higher on the daily | Hattlem | investorshangout | 02/15/2016 2:04:24 PM |
Lucky Jimmy: Right on, I will be watching for them ty. | Lucky Jimmy | investorshangout | 01/22/2016 3:56:06 PM |
News, Short Squeeze, Breakout and More Instantly...
Neurocrine Biosciences Inc. Company Name:
NBIX Stock Symbol:
NASDAQ Market:
Neurocrine Biosciences Inc. Website:
Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH PR Newswire PDUFA Target Action Dates in Late December 2024 Highly Selective CRF 1 Antagonist is the Potent...
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Bios...
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine PR Newswire - CAHtalyst™ Pediatr...